Oncogénesis y drogas antitumorales

  • Mangues Group

Research

Our work focuses on the preclinical development of nanomedicines, which include protein-based self-assembled nanoparticles, and drug-nanoparticle conjugates, for therapy of solid tumors and hematological neoplasias.

All developments pursue their clinical translation and their transfer to the Biotech and Pharma industry. We especially target cancer stem cells that overexpress the chemokine receptor CXCR4, using a targeted drug delivery approach that selectively eliminates these cells, leading to a blockade of metastatic dissemination. Depending on the tumor type, we chemically conjugate small drugs or toxins, or incorporate cytotoxic polypeptides as payloads, to the protein nanocarrier. Using this strategy, we have demonstrated potent prevention of metastasis development and regression of established metastases in colorectal cancer models. We also demonstrated a potent blockade of dissemination in acute myeloid leukemia and diffuse large B-cell lymphoma models.

Collaborations

- Professor Antonio Villaverde, Nanobiotechnology Group. Department of Genetics and Applied Microbiology, Autonomous University of Barcelona

People

NombreRol
Ramon ManguesRamon ManguesGroup Leader
Isolda CasanovaSenior Researcher
Ugutz UnzuetaSenior Researcher
Patricia ÁlamoPostdoctoral Investigator
Lorena AlbaPostdoctoral Investigator
Victor PallarèsPostdoctoral Investigator
Rita SalaPhD Student
Aïda FalgàsPhD Student
Esperanza MedinaPhD Student
Elisa RiojaPhD Student
Yaiza NúñezPhD Student
Luis Miguel CarrascoPhD Student
Annabel GarcíaTechnician
Carlos NavasTechnician

Current projects

Targeted Nanoparticle Combination for the Selective Kiling of Metastasis Stem Cells

Responsable:Ramon Mangues
Código:PI18/00650
Financiadores:
Fecha de inicio:01/01/2019
Fecha de finalización:31/12/2021

Targeted nanocongugates for the selective elimination of stem cells in disseminated

Responsable:Ramon Mangues
Código:PIE15/00028
Financiadores:
Fecha de inicio:01/01/2016
Fecha de finalización:30/06/2020

Desarrollo de un nuevo medicamento selectivo con potente actividad antimetástatica (Nanotrac)

Responsable:Ramon Mangues
Código:RTC-2017-6125-1
Financiadores:
Fecha de inicio:01/01/2018
Fecha de finalización:30/06/2021

Cancer Nanomedicine. From bench to bedsiteCA17140

Responsable:Ramon Mangues
Código:CA17140
Financiadores:
Fecha de inicio:01/01/2019
Fecha de finalización:30/12/2022

Humanized nanomedicines selectively killing CXCR4+ cancer cells for Acute Myeloid Leukemia therapy

Responsable:Jordi Sierra
Código:517C/20190318/1330
Financiadores:
Fecha de inicio:01/04/2021
Fecha de finalización:30/03/2024